



WATCHMAN Pre Screening Checklist

PATIENT NAME		DOB				
) to any of the four crit	eria below, the patient	does not meet t	he WATCHMAN implant eligibil	ity requirements.	
	Patient has Non-Valvular Atrial Fibrillation (NVAF)					
2	Patient has an increased risk for stroke and is recommended for oral anticoagulation (OAC) CHA_2DS_2 -VASc of ≥ 2 (or CHA_2DS_2 -VASc of ≥ 3 for Medicare patients). See table on back page.					
3	Patient is suitable for short-term warfarin therapy but deemed unable to take long-term OAC					
	WATCHMAN Pos	st Implant Drug Regime	n			
	POST-PROCEDURE	THERAPY	DESTINATION	I THERAPY		
	Warfarin + ASA (81-100 mg) daily	Clopidogrel (75 mg) + ASA (300-325 mg) daily	ASA	A (300-325 mg) daily		
				\rightarrow		
	IMPLANT	45 DAYS*	6 MONTHS			
	*At TEE: If leak >5mm, patients r	remain on warfarin + ASA until seal is	documented (leak \leq 5m	m), skipping the Clopidogrel + ASA pharmacothera	ιργ.	
4 YES NO		propriate rationale to nay include one or m		pharmacologic alternative t owing:	o warfarin.	
	History of bleeding or increased bleeding risk (See HAS-BLED table on back page.)					
	High risk of recurrent falls					
	O Documented poor compliance with OAC therapy					
	Inability or difficulty maintaining therapeutic range					
	O Intolerance of warfarin and NOACs					
	Increased bleeding risk not reflected by the HAS-BLED score (e.g. thrombocytopenia, cancer, or risk of tumor associated bleeding in case of systemic anticoagulation)					
	Occupation/lifestyle with increased bleeding risk					
	Severe renal failure					
	O Avoidance of triple therapy after PCI or TAVR					
	Other situations	for which OAC is inapp	ropriate			
Does Your N	IVAF Patient Meet Cri	teria for a WATCHMAN	Referral?			

If so, please refer to: ____



CHA₂DS₂VASc Score (Stroke Risk)

	Condition	Points	Score	Yearly Stroke Risk (%)
С	Congestive Heart Failure	1	0	0
Н	Hypertension (SBP > 160)	1	1	1.3
A ₂	Age ≥ 75 Years	2	2	2.2
D	Diabetes mellitus	1	3	3.2
S ₂	Prior stroke, TIA or thromboembolism	2	4	4.0
V	Vascular disease (PAD,MI)	1	5	6.7
Sc	Sex category (Female)	1	6	9.8
A	Age 65-74 years	1	7	9.6
TOTAL POINTS		8	6.7	
			9	15.2

HAS-BLED Score (Bleeding risk with warfarin)

	Condition	Points	Score
Н	Hypertension	1	0
А	Abnormal renal/liver function (1pt each)	1 or 2	1
S	Hemorrhagic Stroke	1	2
В	Bleeding history or disposition	1	3
L	Labile	1	4
E	Elderly	1	5+
D	Current drugs (medication) or alcohol use (1pt each)	1 or 2	
TOT	AL POINTS		

Score	Yearly Major Bleeding Risk (%)
0	1.13
1	1.02
2	1.88
3	3.74
4	8.7
5+	12.5%

*Major Bleed =ICH or bleeding resulting in a hospitalization, a hemoglobin drop > 2 g/dL, or a blood transfusion. NOTE: A high HAS-BLED score is \geq 3.

Formal Shared Decision Making

The patient must have a formal shared decision making interaction with an independent, non-interventional physician using an evidence-based decision tool on oral anticoagulation in patients with NVAF prior to LAAC. Additionally, the shared decision making interaction must be documented in the medical record. THIS IS NOT A FORMAL SHARED DECISION MAKING DOCUMENT AND CANNOT BE USED FOR RECORDING THE SHARED DECISION MAKING INTERACTION.